Recipharm Expands CDMO Capabilities with New Investments in Pharma Development

• Recipharm is expanding its pharmaceutical development capabilities through targeted investments in advanced technologies.

• The investment aims to enhance services for early- and late-stage product development, including clinical supply.

Recipharm, a global pharmaceutical contract development and manufacturing organisation (CDMO), has announced an expansion of its pharmaceutical development capabilities. This initiative aims to meet the growing demands of both early- and late-stage product development, which includes clinical study supply at small and pilot scales.

The investment will enable Recipharm to offer fully integrated services that cover the entire life cycle of a molecule, from active pharmaceutical ingredient (API) route scouting to commercial manufacturing of pharmaceutical products. Recipharm’s development centres, located strategically in Europe, the US, and India, are equipped with advanced tools and infrastructure that enable science-driven solutions guided by the Quality by Design (QbD) principle. The company utilises its innovative ReciPredict platform, combining material- and process-sciences with statistical tools, modelling, and simulation.

In Bengaluru, India, Recipharm’s centre of excellence for small molecules is expanding its capabilities with a new lab dedicated to sterile product development. This complements recent additions of laboratories focused on Extractables and Leachables, Nitrosamines, and Elemental Impurities, positioning Bengaluru as a flagship location for comprehensive analytical services. Meanwhile, in Zwickau, Germany, the pilot-scale development centre will enhance dry granulation, tableting, and hard capsule filling.

The company has also strengthened its sterile development capabilities across pre-clinical, clinical, and pilot scales for both small and large molecules. Notable investments include a new development lab for sterile formulations in Bengaluru and the installation of GMP lines for vials and pre-filled syringes at the Wasserburg site.